The primary endpoint is the most important outcome measure in a clinical trial, used to test the study\u2019s main hypothesis. It defines what the study aims to prove or refute and forms the basis for statistical planning, in particular sample size calculation. In a regulatory marketing authorisation procedure, the primary endpoint is the key criterion for demonstrating efficacy. The EMA and FDA expect the primary endpoint to be clearly defined in the study protocol, clinically relevant, and measurable using validated instruments. Only a well-chosen, prospectively defined, and rigorously measured primary endpoint allows for a robust, regulatorily acceptable conclusion on the efficacy of a therapy. <\/p>\n
A primary endpoint must meet several requirements. It must be clinically relevant, meaning it captures an aspect of immediate importance to patients, physicians, or public health. Overall survival, symptomatic improvement, or prevention of a clinical event such as myocardial infarction or stroke are examples of clinically directly relevant endpoints. <\/p>\n
In addition, the endpoint must be measurable reliably and reproducibly. For subjective endpoints such as pain or quality of life, the measurement instrument used must be validated. For imaging-based endpoints such as progression-free survival in oncology, clear criteria for image assessment must be defined, typically based on standardised criteria such as RECIST. For all endpoints, the exact time point of measurement, the measurement method, and responsibility for the measurement must be specified in the protocol. <\/p>\n
Clinical trials typically have one primary endpoint and several secondary endpoints. Secondary endpoints provide additional information on efficacy, safety, or quality of life, but are not decisive for the marketing authorisation decision. The distinction is important from a regulatory perspective: only the primary endpoint is subject to the full confirmatory testing procedure with the pre-specified significance level. Secondary endpoints are generally exploratory in nature and are susceptible to multiplicity issues if analysed without adjustment. <\/p>\n
In some studies, there are so-called co-primary endpoints, where both endpoints must be statistically significant for the study to be considered positive. This is the case, for example, in non-inferiority studies, where both the ITT and per-protocol analyses must be positive. Composite endpoints combine multiple clinical events into a single endpoint to increase statistical efficiency, but they are challenging to interpret and must be carefully justified from a regulatory standpoint. <\/p>\n
A surrogate endpoint is a biomarker or measurable parameter used as a substitute for a clinically direct endpoint. Examples include blood pressure as a surrogate for cardiovascular events or CD4 cell count as a surrogate for the clinical course of HIV. Surrogate endpoints have the advantage that they can be measured earlier and with smaller sample sizes. Their disadvantage is that the correlation between the surrogate parameter and clinical outcome is not always assured. Regulators accept surrogate endpoints when their validity as a substitute for clinical endpoints is well supported in the literature. <\/p>\n
In accelerated approval pathways (FDA Accelerated Approval, EMA Conditional Marketing Authorisation), surrogate endpoints may be accepted as the basis for a provisional approval when there is a high unmet medical need. The marketing authorisation holder must then subsequently demonstrate clinical endpoints in confirmatory studies. <\/p>\n
Selecting the primary endpoint is a strategically important decision in clinical development. Early scientific advice from the EMA or national authorities helps to secure the endpoint from a regulatory perspective. Authorities have published clear recommendations for preferred primary endpoints in therapeutic area-specific guidelines. Any deviation from these recommendations must be well justified. Lack of regulatory acceptance of the primary endpoint is one of the most common reasons for marketing authorisation applications to fail. Full-service CROs such as mediconomics advise sponsors on endpoint strategy, preparation for scientific advice, and documentation in the study protocol and statistical analysis plan. <\/p>\n
Validating measurement instruments for primary endpoints is an often underestimated aspect of study planning. If a new assessment instrument or a new imaging method is used as the primary endpoint, its measurement quality must be demonstrated: reliability (consistent measurement on repeated use), validity (does the instrument measure what it is intended to measure?), and responsiveness (does the instrument detect clinically relevant changes?). Regulators require this evidence before use in confirmatory studies. For established instruments such as standardised scales or validated imaging protocols, this effort is not necessary provided the instrument has already been validated for the specific population and indication. <\/p>\n
Can the primary endpoint still be changed after the study has started?<\/strong><\/p>\n In principle, no. A post hoc change to the primary endpoint is considered a serious risk factor for bias and is critically assessed by regulators. If a change is unavoidable for scientific reasons, it must be documented as a formal protocol amendment and approved by the ethics committee and the competent authority. The change must be made before any unblinded data have been reviewed. <\/p>\n What is a composite endpoint and when is it appropriate?<\/strong><\/p>\n A composite endpoint combines multiple clinical events into a single endpoint, for example death, myocardial infarction, or stroke in a cardiovascular endpoint (MACE). This approach increases the number of observable events and improves statistical power. It is appropriate when all components are clinically equivalent and directly meaningful to the patient, and when the overall endpoint convincingly and comprehensively reflects the clinical picture of the disease. If the individual components differ in frequency and clinical relevance, interpretation of the composite endpoint is difficult. <\/p>\n","protected":false},"excerpt":{"rendered":" The primary endpoint is the most important outcome measure in a clinical trial, used to test the study\u2019s main hypothesis. It defines what the study aims to prove or refute and forms the basis for statistical planning, in particular sample size calculation. In a regulatory marketing authorisation procedure, the primary endpoint is the key criterion […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6722","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6722\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6722"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}